Our meta-analysis demonstrated that adjuvant EGFR-TKIs had no impact on OS compared to placebo or adjuvant chemotherapy in the intent-to-treat patients with resected NSCLC regardless of the EGFR mutations status (HR 0.91, 95% CI 0.69–1.20). This evidence concerns the gene EGFR and non-small cell lung carcinoma.